Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients
Sep 2026· Cancer Chemotherapy and Pharmacology· Vol 96· 0 citations· 26 references
Medicine
Abstract
Donor-derived anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy has emerged as one of the most promising treatments for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In this retrospective study, we evaluated the safety and efficacy of donor-derived anti-CD19 CAR T cells manufactured at our local GMP-compliant production facility. Eleven patients with R/R B-ALL received donor-derived anti-CD19 CAR T-cell therapy. Seven of the eleven patients had previously undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). All eleven patients achieved minimal residual disease (MRD) negativity by day 28 post-infusion. Three patients developed grade 1 cytokine release syndrome (CRS), and one patient developed grade 2 CRS. No case of immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. The patient who experienced grade 2 CRS also developed grade 2 graft-versus-host disease (GVHD. At the median follow-up time of 47 months (range, 6-104 months), eight patients remained alive and MRD-negative. Three patients died: one from bone marrow (BM) relapse, one from concurrent BM and central nervous system (CNS) relapses, and one from candidemia. The 5-year overall survival and event-free survival rates were both 70%. In this retrospective study, donor-derived anti-CD19 CAR T-cells produced in a GMP-compliant environment demonstrated a favorable safety profile and high efficacy in treating patients with R/R B-ALL. Larger studies are warranted to confirm these findings.
CD123-directed CAR T-cell therapy is feasible and demonstrates a favorable safety profile in patients with r/r AML and BPDCN, including those with prior alloHCT, according to a phase 1 trial evaluating CD123-targeting chimeric antigen receptor (CAR) T cells in patients with relapsed/refractory AML.
L. Budde, M. D. Del Real, J. Song et al.· Journal of Hematology & Onco...· 0 citations
In this nonrandomized clinical trial, bicistronic CD19/CD22 CAR T-cell therapy induced high rates of minimal residual disease-negative remission, with durable EFS in pediatric B-ALL, and support further evaluation in prospective trials.
Xinyu Wan, Yan-Jing Tang, Jiao-Yang Cai et al.· JAMA Oncology· 1 citation
Background T-cell acute lymphoblastic leukemia (T-ALL) with ABL1 rearrangement is an extremely rare disease, and its clinical significance has not been precisely defined. We report the clinical characteristics of a pediatric patient with T-cell acute lymphoblastic leukemia harboring ABL1 rearrangement and the treatment...
Ming-Yan Zhong, Wen-Ting He, Ling-Ji Zeng et al.· Frontiers in Oncology· 0 citations
XmAb18968 is safe and tolerable with encouraging preliminary efficacy, supporting further investigation of CD38 targeting therapies in this setting, and further investigation of CD38 targeting therapies in this setting is supported.
G. S. Guru Murthy, B. Shah, Talha Badar et al.· Leukemia· 0 citations
The current state-of-the-art of CART-cell therapy for ALL is reviewed and key principles about CART-cell indications, production, outcomes, complications, and relevant issues for shared-care centers on follow-up in the short and long term are summarized.
Antonio Grasso, A. Mishra, Juliana Silva et al.· Pediatrics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.